Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that it has launched its Voriconazole Tablets, 50 mg & 200 mg and Voriconazole Oral Suspension, 40 mg/mL having received an approval from the United States Food and Drug Administration (FDA) earlier to market a generic equivalent of PF Prism C.V’sVfend® Tablets, 50 mg & 200 mg and Vfend®Oral Suspension, 40 mg/mL.

Voriconazole Tablets, 50 mg & 200 mgand Voriconazole Oral Suspension, 40 mg/mL are the AB rated generic equivalent ofPF Prism C.V’sVfend® Tablets, 50 mg & 200 mg and Vfend®Oral Suspension, 40 mg/mL.It is indicated foruse in patients 12 years of age and older in the treatment of the following fungal infections:

• Invasive Aspergillosis
• Candidemia in Non-neutropenic patients and the followingCandidainfections: Disseminated infections in skin and infections in abdomen, kidney, bladder wall and wounds
• Esophageal Candidiasis
• Serious fungal infections caused byScedosporium apiospermum(Asexual form ofPseudallescheria boydii) andFusariumspp. includingFusarium solaniin patients intolerant of or refractory to other therapy

Vfend® Tablets, 50mg & 200mg had US sales of USD 81 million (IMS MAT September 2016) while Vfend®Oral Suspension, 40 mg/mL had US sales of USD 15.2 million (IMS MAT September 2016).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 6^th and the 8^th largest generics pharmaceutical company by market capitalization and sales globally (September 30^th, 2016, Bloomberg). The Company is the 5^th largest pharmaceutical player in the US by prescriptions (4.68% market share – IMS Health, National Prescription Audit, March 2016); the 3^rd largest Indian pharmaceutical company by revenues; the 6^th largest generic pharmaceutical player in Japan and the 4^th largest generic pharmaceutical company in South Africa (IMS Health, March 2016).

For the financial year ended 31^st March, 2016, Lupin’s Consolidated sales and Net profit stood at Rs. 136,539 million (USD 2.09 billion) and Rs. 22,607 million (USD 345 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinlimited

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Shamsher Gorawara
Head – Corporate Communications
Ph: +91-98 20 338 555
Email: shamshergorawara@lupin.com

or

Arvind Bothra
Head – Investor Relations and M&A
Ph: +91-70 45 656 895
Email: arvindbothra@lupin.com

*Safe Harbor Statement

Vfend®is the registered trademark of Pfizer Ireland Pharmaceuticals